SCHEMBL6416374

SCHEMBL6416374

Oc1c(Br)cc(Cl)cc1C=NNc1nc2nonc2nc1Nc1cccc(Br)c1

nearest known ligand 0.41

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
MAPT P10636 9/20 0.41
SMN1; SMN2 Q16637 4/20 0.41
POLB P06746 3/20 0.41
TP53 P04637 3/20 0.41
MEN1 O00255 6/20 0.40
KMT2A Q03164 6/20 0.40
NPC1 O15118 5/20 0.40
RAB9A P51151 5/20 0.40
GAA P10253 2/20 0.40
GFER P55789 2/20 0.40
LMNA P02545 2/20 0.39
HTT P42858 2/20 0.39
MITF O75030 1/20 0.39
ALDH1A1 P00352 1/20 0.39
CCR2 P41597 1/20 0.37
CCR5 P51681 1/20 0.37
EGFR P00533 4/20 0.36
KDM4E B2RXH2 2/20 0.35
MAPK1 P28482 2/20 0.35
TDP1 Q9NUW8 2/20 0.35

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL6416370 1.00 MAPT (0.41) MAPTSMN1; SMN2POLBTP53MEN1
SCHEMBL6415083 0.89 MEN1 (0.47) MAPTSMN1; SMN2POLBTP53MEN1
SCHEMBL6414687 0.88 SMN1; SMN2 (0.41) MAPTSMN1; SMN2POLBTP53MEN1
SCHEMBL6414734 0.83 MEN1 (0.48) MAPTSMN1; SMN2POLBTP53MEN1
SCHEMBL6432678 0.83 MEN1 (0.51) MAPTSMN1; SMN2POLBMEN1KMT2A
SCHEMBL6415071 0.83 MAPT (0.35) MAPTSMN1; SMN2POLBTP53MEN1
SCHEMBL6415067 0.83 MAPT (0.35) MAPTSMN1; SMN2POLBTP53MEN1
SCHEMBL6412900 0.81 MEN1 (0.45) MAPTSMN1; SMN2POLBTP53MEN1
SCHEMBL6416047 0.79 MAPT (0.41) MAPTSMN1; SMN2POLBTP53MEN1
SCHEMBL6416048 0.79 MAPT (0.41) MAPTSMN1; SMN2POLBTP53MEN1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20050143382-A1 Heterocyclic compounds as pharmaceutically active compounds 4SC AG (DE) 2005-06-30 US disclosed
WO-2005044270-A1 OXADIAZOLOPYRAZINE DERIVATIVES AS PHARMACEUTICALLY ACTIVE COMPOUNDS 4SC AG (DE) 2005-05-19 WO disclosed
EP-1529531-A1 Oxadiazolopyrazine derivatives as pharmaceutically active compounds 4SC AG (DE) 2005-05-11 EP disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20050143382-A1 Heterocyclic compounds as pharmaceutically active compounds NR5A2, NR1H2, NR2C2 MAPT 4420/4885SMN1; SMN2 4369/4885POLB 3589/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.